[HTML][HTML] Vascular cognitive impairment (VCI)

T Rundek, M Tolea, T Ariko, EA Fagerli, CJ Camargo - Neurotherapeutics, 2023 - Elsevier
Vascular cognitive impairment (VCI) is predominately caused by vascular risk factors and
cerebrovascular disease. VCI includes a broad spectrum of cognitive disorders, from mild …

Alzheimer's Disease and Vascular Aging: JACC Focus Seminar

M Cortes-Canteli, C Iadecola - Journal of the American College of …, 2020 - jacc.org
Alzheimer's disease, the leading cause of dementia in the elderly, is a neurodegenerative
condition characterized by accumulation of amyloid plaques and neurofibrillary tangles in …

Alzheimer's pathogenic mechanisms and underlying sex difference

D Zhu, A Montagne, Z Zhao - Cellular and Molecular Life Sciences, 2021 - Springer
AD is a neurodegenerative disease, and its frequency is often reported to be higher for
women than men: almost two-thirds of patients with AD are women. One prevailing view is …

Epigallocatechin-3-Gallate (EGCG): New therapeutic perspectives for neuroprotection, aging, and neuroinflammation for the modern age

A Payne, S Nahashon, E Taka, GM Adinew… - Biomolecules, 2022 - mdpi.com
Alzheimer's and Parkinson's diseases are the two most common forms of neurodegenerative
diseases. The exact etiology of these disorders is not well known; however, environmental …

Adaptive immune cells shape obesity-associated type 2 diabetes mellitus and less prominent comorbidities

S SantaCruz-Calvo, L Bharath, G Pugh… - Nature Reviews …, 2022 - nature.com
Obesity and type 2 diabetes mellitus (T2DM) are increasing in prevalence owing to
decreases in physical activity levels and a shift to diets that include addictive and/or high …

Current understanding of the physiopathology, diagnosis and therapeutic approach to Alzheimer's disease

V García-Morales, A González-Acedo… - Biomedicines, 2021 - mdpi.com
Alzheimer's disease (AD) is the most common cause of dementia. It is characterized by
cognitive decline and progressive memory loss. The aim of this review was to update the …

Mitochondrial aldehyde dehydrogenase (ALDH2) rescues cardiac contractile dysfunction in an APP/PS1 murine model of Alzheimer's disease via inhibition of ACSL4 …

Z Zhu, Y Liu, Y Gong, W Jin, E Topchiy… - Acta Pharmacologica …, 2022 - nature.com
Alzheimer's disease (AD) is associated with high incidence of cardiovascular events but the
mechanism remains elusive. Our previous study reveals a tight correlation between cardiac …

ALDH2 contributes to melatonin-induced protection against APP/PS1 mutation-prompted cardiac anomalies through cGAS-STING-TBK1-mediated regulation of …

S Wang, L Wang, X Qin, S Turdi, D Sun… - Signal transduction and …, 2020 - nature.com
Ample clinical evidence suggests a high incidence of cardiovascular events in Alzheimer's
disease (AD), although neither precise etiology nor effective treatment is available. This …

Safety and efficacy of lecanemab for Alzheimer's disease: a systematic review and meta-analysis of randomized clinical trials

Y Qiao, Y Chi, Q Zhang, Y Ma - Frontiers in aging neuroscience, 2023 - frontiersin.org
Objective We performed a systematic review and meta-analysis of the cognitive
effectiveness and safety of lecanemab on subjects with Alzheimer's disease (AD). Methods …

Causes and consequences of baseline cerebral blood flow reductions in Alzheimer's disease

O Bracko, JC Cruz Hernández, L Park… - Journal of Cerebral …, 2021 - journals.sagepub.com
Reductions of baseline cerebral blood flow (CBF) of∼ 10–20% are a common symptom of
Alzheimer's disease (AD) that appear early in disease progression and correlate with the …